Humacyte, Inc. Class Action Lawsuit - HUMA

The filed complaint alleges that Humacyte, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) the FDA’s review of the biologics license application would be delayed while Humacyte remediated these deficiencies; and (3) as a result, there was a substantial risk to FDA approval of acellular tissue engineered vessel for vascular trauma; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

In order to be eligible to join the HUMA class action lawsuit, you must have incurred a loss on shares of Humacyte, Inc. purchased during the class period listed above.

If you suffered a loss in Humacyte, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until January 17, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.